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ABSTRACT 
It has been 22 years since the first human 
cytomegalovirus (HCMV) full genome sequence 
was published. Together with the first sequence 
also came the first prediction of the coding 
capacity of this intriguing herpesvirus, harbouring 
the largest genome of all human-infecting viruses. 
Through the years, the HCMV genome map was 
refined, but it is still far from complete. 
Comparisons of the genomes of highly passaged 
and attenuated laboratory strains with those of 
recent clinical isolates have shown the former 
underwent substantial rearrangements with gene 
deletions and duplications. It became clear that 
different clinical isolates display remarkable genetic 
variability in large portions of their genomes. This 
led to a quest for clinical correlates of different 
genetic variants. Until now, this approach did not 
give satisfactory results and it is still not clear if 
certain genetic variants are associated with distinct 
disease outcome. More recently, extra levels of 
complexity have been added to the existing 
picture of HCMV genetic variability. Infections 
with multiple HCMV strains seem to be very 
common and the dynamics of different strains 
show unpredictable and stochastic behaviour. Deep 
sequencing efforts have unveiled an extensive 
intrapatient genetic variability, which was 
unexpected for a dsDNA virus. Recent efforts to 
elucidate the HCMV transcriptome have painted a 
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sophisticated picture with lots of splicing and 
alternative transcripts. It is clear that we are only 
unveiling the tip of the iceberg regarding HCMV 
genomics and transcriptomics and their role in the 
myriad viral functions. Recent advances in technology 
and bioinformatics provide us with the tools to 
begin to tackle these interesting questions. 
 
KEYWORDS: cytomegalovirus, human herpesvirus 
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ABBREVIATIONS 
HCMV :  Human cytomegalovirus 
dsDNA :  double-stranded DNA 
UL :  unique long 
US :  unique short 
TRL/IRL :  terminal/internal repeat long 
IRS/TRS :  internal/terminal repeat short 
ORF :  open reading frame 
CCMV :  chimpanzee cytomegalovirus 
UL128L :  UL128 locus 
IGA :  Illumina Genome Analyzer 
NGS :  next-generation sequencing 
miRNA :  microRNA 
 
INTRODUCTION 
HCMV is the prototype member of the herpesvirus 
subfamily Betaherpesvirinae [1]. These viruses are 
characterized by lengthy replication cycles, are 
strictly cell-associated in vitro and do generally 
not cross host species barriers. HCMV is distributed 
worldwide and infections are common, with 
seroprevalences of 45-100% in women of 
reproductive age, depending on geographic location, 
socio-economic background and age [2]. Infections 
of healthy children and adults are usually 
 
Laboratory of Clinical Virology, Rega Institute for Medical Research, KU Leuven, Belgium 
Steven Sijmons, Marc Van Ranst and Piet Maes* 
 
*Corresponding author: Piet Maes, 
Laboratory of Clinical Virology,  
Minderbroedersstraat 10,  
BE-3000 Leuven, Belgium. 
pmaes3@uzleuven.be 
 
Current Topics in  
V i r o l o g y
Vol. 1, 2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Steven Sijmons et al. 
cloning and chain-termination sequencing of the 
extensively passaged laboratory strain AD169, 
which was and is highly used in HCMV research. 
At the time, it was the largest contiguous sequence 
ever derived. The authors calculated that the effort 
to sequence this single genome corresponded to 
one person working for 12 years on the project 
[7]. A first genetic map of HCMV was derived, 
containing 208 open reading frames (ORFs) that 
were thought to encode proteins. 14 of these ORFs 
were duplicated in the TRL/IRL repeats. Like 
other herpesviruses, most of the HCMV genes are 
positioned end-to-end, with little non-coding 
sequence. A striking feature of the HCMV genome 
map was the apparent duplication and divergence 
of a large set of genes, which were grouped in 
gene families. 52 of the predicted ORFs could be 
grouped into 9 gene families. 
Comparisons of genome regions of AD169 with 
Towne and Toledo strains revealed major genome 
rearrangements [8, 9]. The highly passaged and 
low virulent AD169 and Towne strains, which 
had been developed as vaccine candidates, were 
missing a segment of 15 and 13 kbp respectively 
which was present in the Toledo strain (Fig. 1). 
Toledo was passaged significantly less (exact 
passage numbers are not known) and had produced 
clinically apparent disease in clinical trials. These 
missing segments were located at the junction of 
the UL and b’ (IRL) regions. Total genome length 
did not change significantly, since the b repeats 
were much smaller in Toledo. Inspection of five 
additional clinical isolates showed that they all 
contained the 15 kbp region missing in AD169. 
Apparently, the extensive passaging and loss of 
virulence of AD169 and Towne had been 
 
asymptomatic but the virus establishes a lifelong 
persistence as a latent infection, from which it can 
reactivate to spread infectious progeny. HCMV 
can cause serious sequelae during infection of 
immunocompromised individuals and fetuses [3]. 
Worldwide, HCMV is the most common congenital 
infection, with an overall birth prevalence of 
0.64% [4]. 
Like other herpesviruses, HCMV has a characteristic 
virion morphology consisting of a linear dsDNA 
genome wrapped in an icosahedral capsid, an 
amorphous tegument layer and a lipid bilayer 
envelope. The HCMV genome has a size of 
approximately 235 kbp, which makes it the 
longest genome of all human viruses. It contains 
two unique regions, termed unique long (UL) and 
unique short (US), both flanked by a pair of inverted 
repeats ab (TRL/IRL) and ac (IRS/TRS). The overall 
genome arrangement can be described as ab-UL-
b’a’c’-US-ca where primes designate inverted 
orientations (Fig. 1). UL and US can be inverted 
relative to each other giving rise to four genomic 
isomers [5]. 
In this review, we want to give an overview of our 
understanding of the HCMV genome, its coding 
capacity and diversity, which has developed over 
the past 20 years. The recent progress made 
through the application of novel high-throughput 
sequencing technologies will be highlighted. 
 
HCMV genome sequencing and prediction of 
coding capacity 
The first complete genome sequence of HCMV was 
published in 1990 by Chee and colleagues [6]. 
The sequence was derived through M13 shotgun 
 
Fig. 1. Schematic representation of the overall genome rearrangement of HCMV clinical isolates and highly 
passaged laboratory strains, exemplified by strain AD169. The deletion and compensatory duplication that 
arose during extensive passage are indicated. ab corresponds to TRL, b’a’ to IRL, a’c’ to IRS and ca to IRL. 
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clinical isolates after cloning them as bacterial 
artificial chromosomes [12]. They reported a set 
of 252 ORFs that were conserved in all four 
clinical isolates including a set of 29 that were 
previously unrecognized. Comparison of the 
conserved ORFs of the four clinical isolates also 
revealed that while many of the ORFs were highly 
conserved, a subset displayed remarkable variability 
among different strains. These variable ORFs were 
found scattered throughout the HCMV genome. 
Dolan et al. determined the complete genome 
sequence of a minimally passaged isolate (passage 3) 
from a congenitally infected infant, termed strain 
Merlin [13]. Additionally, they studied substantial 
regions of the genome in other isolates, including 
unpassaged strains. They also found high variation 
in a subset of genes, many of which encode secreted 
and membrane-associated proteins. Based on 
these combined data, the authors refined previous 
annotations and defined a set of 165 genes 
reflecting the wild-type HCMV coding capacity. 
The sequence of strain Merlin has become the 
reference sequence for wild-type HCMV and its 
annotation is constantly updated incorporating 
new insights. The genetic map of HCMV as 
currently annotated on the HCMV reference 
sequence (NC_006273) contains 170 genes and is 
presented in Fig. 2. 
While large genome rearrangements have occurred 
in highly passaged laboratory strains like AD169 
and Towne, these strains also show several 
mutations affecting other genes than the ones in 
the UL/b’ region. AD169 is mutated in RL5A, 
RL13, UL36 and UL131A, whereas Towne 
displays frameshifts in RL13, UL1, UL130, US1 
and US9 [14]. In fact, the Toledo strain that led to 
the discovery of the large deletion in AD169 and 
Towne itself had an inversion in the UL/b’ region, 
resulting in disruption of UL128 [8, 9]. Furthermore, 
Toledo is mutated in RL13 and UL9. Even the 
minimally passaged Merlin strain has a mutation 
in UL128 [13]. Most strains passaged in fibroblast 
cell lines seem to contain mutations in 1 of 3 
neighbouring genes, UL128, UL130 and UL131A, 
the so-called UL128 locus (UL128L). The products 
of this gene locus form a complex with the viral 
glycoproteins gH and gL that is required for entry 
into endothelial and epithelial cells, but not for 
entry into fibroblasts [15]. When developing a 
accompanied by the loss of a region in the 3’ end 
of UL. An inverted copy of a region in the 5’ end 
of UL had replaced this region effectively enlarging 
the b repeats. This compensatory duplication is 
probably a consequence of the genome length 
restrictions that are imposed by the packaging 
process and virion architecture. The 15 kbp region 
(commonly referred to as the UL/b’ region) was 
predicted to encode 19 additional ORFs. While 
these ORFs are evidently dispensable for growth 
in fibroblasts, they immediately attracted interest 
as possible modulators of cell tropism, immune 
regulation and latency. 
The initial prediction of 208 coding ORFs by 
Chee et al. [6] was effectively based on the 
criteria of a minimum polypeptide length of 100 
amino acids and a maximal overlap of 60%. The 
authors admitted these criteria could exclude 
smaller or highly spliced functional ORFs. 
Furthermore, it was unsure whether all predicted 
ORFs encoded bona fide proteins. Different 
complementary approaches were taken to achieve 
more accurate predictions of the HCMV coding 
capacity. In a first approach, the genome sequence 
of chimpanzee cytomegalovirus (CCMV), the 
closest known relative of HCMV, was determined 
and compared with the AD169 sequence 
complemented by the Toledo UL/b’ region [10]. 
The rationale of this method is that functional 
ORFs are conserved during evolution so that 
ORFs conserved between HCMV and CCMV are 
very likely functional. The authors concluded 51 
of the proposed ORFs are unlikely to encode 
proteins, modified 24 other ORFs and defined 10 
novel ORFs. A preliminary estimate of 164 to 167 
genes for wild-type HCMV was proposed. In a 
similar approach, the coding potential of AD169 
was reassessed using a gene-finder algorithm that 
predicts the likelihood of the functionality of 
ORFs through matching with a database of amino 
acid patterns [11]. Orthologues of these predicted 
ORFs were then searched in the genomes of 
chimpanzee, rhesus and murine cytomegalovirus. 
This study proposed an estimate of 192 unique 
ORFs that are potentially encoding and results 
were generally in agreement with the study based 
on the CCMV comparison. The same authors also 
took a different approach by sequencing two 
laboratory strains and four briefly passaged 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Genetic map of wild-type HCMV. This map is based on the current annotation of reference strain 
Merlin (NC_006273). Genes are designated in light gray, large non-coding RNAs and the lytic origin of 
replication (oriLyt) in dark gray. 
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mutational dynamics during passaging of four 
clinical strains in fibroblasts, epithelial and endothelial 
cells [17]. They confirmed the invariable mutation 
of RL13 in all cell types and UL128L in fibroblasts 
and demonstrated the suppressive effects on 
growth in fibroblasts were at least partially 
independent. Additionally, they identified several 
other regions of the genome that mutated in some 
but not all strains. These results showed that all 
clinical isolates were genetically unstable during 
passage in different cell types. Strain sequences 
determined were still the product of PCR-based 
amplification and traditional Sanger sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BAC vector of the Merlin strain, it was noted that 
it also contained a defective RL13 gene [16]. The 
authors went back to the original Merlin isolate 
and identified that, while the RL13 consensus 
sequence was wild-type, different clones all 
contained mutations at different positions in 
RL13. When RL13 was repaired, it repressed 
HCMV replication in various cell types and RL13 
mutants rapidly and invariably re-emerged. Repair 
of UL128L only repressed replication in 
fibroblasts and mutations were again acquired, 
although somewhat less rapidly than for RL13. 
Dargan et al. elaborated on this by characterizing 
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isolates, even from unamplified material containing 
only 3% HCMV DNA. It is, however, clear that 
some enrichment or amplification step is necessary 
to make the sequencing of HCMV strains directly 
from clinical material achievable in high-
throughput. This study confirmed the fact that all 
passaged strains contained one or more mutations. 
Furthermore, some evidence did point at a possible 
presence of mutations in the original clinical 
isolates. Some mutations were indeed shared 
between samples from independent clinical settings 
and one of the unpassaged strains was mutated in 
RL5A and UL111A. 
Another NGS platform, the 454 GS-FLX (Roche) 
was used to determine the first full genome 
sequence of an Asian HCMV strain [20]. This 
strain was plaque purified before a short passage 
on fibroblasts and contained two mutated genes 
(UL1 and UL119). 
While these previous studies focused on the 
determination of a consensus sequence from a 
viral population, NGS also offers new possibilities 
in deep sequencing of viral populations. NGS was 
first utilized to characterize HCMV populations 
by Görzer et al. [21]. Subsequently, Renzette 
et al. took this approach to a genome-wide 
perspective [22]. This added three HCMV full 
genome sequences, or major genome types as the 
authors refer to them, to the collection on GenBank. 
Details of these two studies are elaborated in the 
corresponding part about intrahost diversity. All 
HCMV full genome sequences currently published 
are presented in Table 1. 
 
Interhost diversity and clinical significance 
Like stated earlier, full genome comparisons of 
HCMV strains led to the understanding that 
substantial regions of the genome were highly 
variable between independent strains [12, 13]. It 
was already known that some of the genes 
encoding viral glycoproteins are not genetically 
homogeneous and that these polymorphisms exist 
as highly diverged clusters of alleles, so called 
genotypes [23-25]. Some of the genes in the 
UL/b’ region also attracted interest in this regard 
[26-28]. In Fig. 3, the evolutionary divergence of 
all genes on the HCMV genome is presented, 
based on a set of 39 full genome sequences of 
clinical HCMV strains. Next to some of the genes 
In fact, this study somehow marks the end 
of an era in HCMV genomic research, because 
simultaneously the first reports were being 
published making use of a completely new 
generation of sequencing technologies. 
 
Next-generation sequencing in HCMV 
genomics 
The advent of new, massively parallel sequencing 
technologies in the second half of the past 
decennium opened up new possibilities in high-
throughput and deep sequencing [18]. These 
technologies, of which the 454 (Roche) and 
Illumina (Solexa) platforms were the front-
runners, generate an enormous amount of short 
sequence reads from minimal input materials 
without the need for laborious cloning procedures. 
The newly emerging high-throughput sequencing 
technologies were first applied to HCMV 
genomics in 2009. The Illumina Genome Analyzer 
(IGA) (Solexa) was used to elucidate the presence 
of two variants in preparations of the Towne 
strain and identified a new, more genetically 
intact variant of AD169 called varUC [14]. 
In a next step, the usefulness of next-generation 
sequencing (NGS) for sequencing the complete 
genomes of clinical HCMV isolates was evaluated 
using IGA, compared to a PCR-based amplification 
and Sanger sequencing approach [19]. Isolates 
were sequenced both after cell culture passage and 
directly from clinical material. While the PCR-
based approach was successful, even with clinical 
samples containing only 3% of HCMV DNA, it 
proved to be very laborious. IGA sequencing 
provided a much more efficient alternative for 
sequencing HCMV strains directly from clinical 
isolates, although assembly of the enormous 
amount of NGS short sequence reads was not 
straightforward. Due to the inherent variability of 
HCMV isolates, direct mapping of NGS reads on 
a reference sequence did not yield satisfactory 
results. In stead, the authors devised an approach 
in which NGS reads were initially assembled 
without the use of a reference sequence, i.e. de 
novo assembly. The sequences produced via this 
method were then used to assist reference-
dependent assembly of the original NGS reads. 
This approach proved to be successful in 
determining the sequence of clinical HCMV 
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Fig. 3. Average codon-based evolutionary divergence of HCMV genes. The average number of non-synonymous 
substitutions per non-synonymous site dN was calculated for each HCMV gene based on 39 full genome sequences 
of recent clinical isolates. These included strains Merlin, 3157, 3301, AF1, HAN13, HAN20, HAN38, JP, U8, 
U11, VR1814, JHC, U01, U04 and U33 (Table 1) and 24 unpublished, in-house derived full genome sequences. 
Analyses were conducted using the Nei-Gojobori model [72]. Divergences were calculated using MEGA5 [73]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human cytomegalovirus genomics
which is not surprising, considering that studies 
usually have focused on one or two gene products. 
Taking into account the number of HCMV genes 
and the substantial variability in a large subset of 
them, establishing any viral prognostic marker 
will need a more comprehensive approach taking 
into account a larger set of variable genes, if not 
full genome sequences. With the current progress 
in high-throughput sequencing technologies, this 
kind of endeavour could become feasible in the 
near future. 
 
Multiple infections and intrahost diversity 
The search for viral determinants of pathogenicity 
gets even more complicated when we have a look 
at HCMV diversity within an individual host. In 
recent years, it has become increasingly clear that 
infections with multiple HCMV strains are 
common, both in immunocompromised and 
immunocompetent individuals (reviewed in [37]). 
The question whether these multiple infections are 
mostly the product of transmission of multiple 
strains at the same time or a consequence of 
sequential infection events, remains unresolved, 
but it seems that both are possible [48, 49]. It has 
been proposed that mixed infections could be 
disadvantageous for the patient, possibly through 
trans-complementation between strains [50]. This 
disadvantage is supported by studies looking at 
the effect of strain multiplicity on outcome in 
transplant recipients [51-54]. 
NGS technologies are particularly well suited for 
studying the dynamics of mixed viral populations, 
since the vast amount of NGS reads ensure multiple 
coverage of the same region of the genome or 
gene of interest. Görzer et al. made use of the 454 
GS-FLX platform (Roche) to sequence amplicons 
of hypervariable HCMV genes UL73 (gN), UL74 
(gO) and UL139 in lung transplant recipients [21]. 
They observed complex mixtures of up to six 
genotypes in one patient, with maximally 2 types 
making up the majority of the population. 
Comparison of serial samples of the same patient 
showed substantial changes in the abundance of 
genotypes over time. It is far from clear what 
processes shape this differential replication of 
individual strains in multiple infections. 
While genotypes at individual loci can give an 
idea of intrahost strain diversity, much more 
 
encoding viral glycoproteins (mainly gN/pUL73 
and gO/pUL74) and genes in the UL/b’ region 
(most notably UL146 and UL139), the high 
variability of the genes at the 5’ end of the UL 
region is remarkable. These genes form the RL11 
family, characterized by the presence of the RL11 
domain [29]. Several studies already reported 
about the clustered nature of polymorphisms in 
this region of the HCMV genome, but although 
roles in cell tropism and immune evasion 
have been proposed for some members, functions 
of the RL11 family are still poorly characterized 
[30-32]. 
Considering the high variability in some of the 
HCMV genes, it is quite remarkable that HCMV 
genotypes seem to be stable, both within a person 
as within the population over time [27, 33]. The 
same genotypic sequences have been found in 
distinct geographic regions and until now there is 
no proof of genotypes associated with specific 
locations [34-36]. Apparently, the selective forces 
that have shaped this variability are not active 
anymore but exerted their effects a long time ago. 
The current hypothesis states that genotypes were 
formed through immune selection in populations 
of early humans or their predecessors, have been 
shaped by founder and bottleneck events, and 
have been distributed by the worldwide migrations 
of human populations in more recent times [35, 
37, 38]. Moreover, genetic linkages between 
different HCMV loci seem to be very rare, mainly 
limited to regions in close proximity to each other 
[27, 32, 39]. Recombination has probably played 
an important factor in HCMV evolution and has 
generated a virtually infinite number of strains by 
combining genotypes at different sites [39-41]. 
A plethora of studies have been carried out to 
investigate potential correlations between viral 
genotypes and pathogenicity, focusing on genes 
encoding viral glycoproteins and immune 
modulatory proteins [42-45]. These studies were 
mainly motivated by the prospect of finding viral 
prognostic markers for severity of infection, 
which could help tailor medical interventions. We 
will not elaborate further on them here and refer 
to some excellent reviews that cover this matter 
extensively [37, 46, 47]. From the collected data, 
we can conclude that potential relationships between 
HCMV genotypes and pathogenicity remain elusive, 
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negative selection prevents these mutants from 
reducing the overall fitness of the population [22]. 
Further elucidation of the forces that are shaping 
HCMV viral populations in different patient groups 
is necessary to improve our understanding of the 
evolutionary dynamics of this large dsDNA virus. 
 
HCMV transcriptomics 
For many protein-coding ORFs, prediction by 
comparative genomic and pattern-based similarity 
approaches as described earlier has been 
confirmed by information on the expression and 
function of their products. A large fraction of 
predicted genes remain, however, speculative and 
their transcriptional profile has not been studied in 
detail. While ORF-searching algorithms based on 
genomic DNA sequences certainly have their 
virtue in deciphering the coding capacity of an 
organism, there is mounting evidence that these 
approaches yield genomic maps that are an 
oversimplification of reality. An extra level of 
complexity only becomes apparent when 
transcriptional patterns are studied. For HCMV, 
some complex transcriptional processes have been 
discovered (reviewed in [56]): multiple transcripts 
sharing common 5’ or 3’ ends, complex and 
adaptable splicing patterns, antisense transcription 
and transcription of non-coding and miRNAs. 
When cloning and sequencing cDNA libraries 
derived from HCMV transcripts, Zhang et al. 
observed that a striking 45% of clones came from 
genomic regions thought to be non-coding [57]. 
Perhaps even more surprising, 55% of clones 
were derived from transcripts antisense to 56 
known or predicted ORFs. Through the use of 
NGS tools, Gatherer et al. brought full genome 
resolution to HCMV transcriptome studies [58]. 
They confirmed the presence of antisense 
transcription throughout the genome, although 
generally transcribed at a lower level than their 
sense counterpart and overall accounting for 8.7% 
of transcription. The observed abundance of 
antisense transcription leads to the hypothesis that 
this could be a previously unrecognized viral 
mechanism for gene regulation. This idea is 
fostered by the growing understanding of the roles 
of antisense transcription as an important 
epigenetic factor in other pro- and eukaryotes 
(reviewed in [59]). At the moment, the role of 
 
information can be extracted from a genome-wide 
perspective. Renzette et al. used the throughput of 
the Illumina GAII platform (Solexa) to sequence 
amplicons covering the complete genomes of three 
congenitally infected infants [22]. To distinguish 
true HCMV variants from PCR- and/or sequencing 
errors, they developed an error-filtering algorithm 
based on the resequencing of BAC clones of 
AD169 and Toledo. Mismatches in the sequences 
of the BAC clones were considered errors and 
used to establish filtering thresholds for the 
variants in the unknown samples. Using these 
filtering protocols, the authors found the HCMV 
populations in infants to have genetic diversity 
estimates comparable to those of RNA viruses 
like HIV and dengue virus, which was a 
surprising result for a dsDNA virus encoding a 
polymerase with proofreading capacity. These 
populations consisted of one highly abundant type 
and a high number of low-level variants, which is 
essentially in agreement with the findings of 
Görzer et al. [21]. Because of the fractional nature 
of NGS reads, it is impossible to infer whether 
highly abundant types at different locations 
actually form a single genome-wide type. At the 
moment, it is not clear how this diversity is 
generated and what role these low-level variants 
play in natural infections. They could provide the 
virus with a means of rapidly evolving to changes 
in its environment, but could also prove to be 
defective variants that are just a by-product of 
productive viral replication. More research is 
warranted to confirm these estimates of viral 
population diversity in other clinical and non-
clinical settings. In this regard, the authors already 
applied their diversity estimation algorithm to 
HCMV populations in malignant gliomas and 
found these to be significantly less diverse [55]. 
It would also be interesting to elucidate if and 
how selection is acting on these populations. In 
this regard, Renzette et al. already provided some 
preliminary results that could point to positive 
selection acting on the intrahost populations [22]. 
This is obviously in contrast to the stability and 
negative selection that seem to shape genotypes in 
interhost populations [35]. The authors provide the 
hypothesis of a balance between both where 
intrahost diversity is promoted as an evolutive 
advantage in an ever-changing environment and 
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multiple ORFs were translated from the long non-
coding RNAs 1.2, 2.7 and 4.9. A large fraction of 
these ORFs were confirmed through high-
resolution tandem mass spectrometry or tagging 
approaches. The authors also stress the role of 
alternative 5’ ends in the temporal regulation of 
viral gene expression. By changing the 5’ end of 
transcripts during the course of infection, the virus 
can express different proteins from overlapping 
coding regions in a temporal fashion. 
Next to the longer non-coding RNAs, it was shown 
that viruses also encode microRNAs (miRNAs) 
[62]. MicroRNAs are small RNAs (approx. 23 nt) 
that play a part in post-transcriptional repression 
of gene expression through targeting of protein-
coding mRNAs [63]. MiRNAs enable regulation 
of viral and cellular genes while being non-
immunogenic and only requiring minimal space in 
the viral genome. The HCMV genome is known 
to contain miRNA precursors that are processed to 
mature miRNAs during infection [64, 65] (reviewed 
in [66]). Stark et al. recently studied the profile of 
small RNAs (both viral and host-derived) during 
HCMV infection through NGS analysis (IGA) 
[67]. They found that 20% of the small RNA 
population encoded viral miRNAs and designated 
two novel HCMV miRNAs. At the moment, 22 
mature HCMV miRNAs are characterized. The 
authors provided evidence that all HCMV 
miRNAs are incorporated into the endogenous 
host silencing machinery demonstrating their 
functionality. Furthermore, novel small viral RNAs 
were identified that were distinct from miRNAs. 
These were especially observed across long non-
coding RNAs like RNA2.7. While these could be 
degradation products from this highly transcribed 
region of the HCMV genome, other highly 
transcribed regions were not found to produce 
these small RNAs. These results are in agreement 
with the observations made by Stern-Ginossar 
et al. in the ribosome profiling study [61]. Regarding 
their ubiquity, these small RNAs (and their 
putative protein products) could play important 
regulatory roles during infection but up to now 
there is no data available to strengthen this 
hypothesis. 
There are some caveats to the wealth of data that 
are emanating from these HCMV transcriptome 
studies. As long as these RNA characterizations 
 
antisense transcripts in HCMV infections is, 
however, still largely uncharacterized. 
Next to the potential role of antisense transcripts, 
the full genome HCMV transcriptome study 
provided some other important insights [58]. It 
was observed that 65.1% of viral transcripts were 
involved in the production of four non-coding 
RNAs (RNA2.7, RNA1.2, RNA4.9 and RNA5.0) 
(Fig. 2). These RNAs do not overlap substantially 
with known ORFs and are therefore thought not to 
function through translation. A staggering 46.8% 
of viral transcripts were dedicated to the production 
of RNA2.7 that has been shown to regulate 
mitochondria-induced cell death thereby inhibiting 
apoptosis [60]. This large involvement of antisense 
and non-coding RNAs reciprocally implied that 
only one-third of viral polyadenylated RNAs were 
translated into proteins. Furthermore, a large 
number of unrecognized splicing sites were 
discovered and confirmed through additional 
experimentation, unveiling splicing is much more 
common and complex than previously recognized. 
Splice sites are now characterized in about one-
third of ORFs and while necessary for expression 
in some, they could have more subtle regulatory 
roles in other. Altogether, this study revealed 
HCMV transcription to be much more complex 
than expected, providing the virus with a wealth 
of tools to regulate its functions. The 
transcriptome profiling also led to the designation 
of four new genes (RL8A, RL9A, UL150A and 
US33A), bringing the estimate of HCMV genes to 
170 (Fig. 2). This indicates the added value of 
transcriptomics in genome annotation. 
The complexity of the HCMV coding capacity 
was recently confirmed by characterization of 
the translation products that arise during infection 
[61]. The authors used a technique called 
ribosome profiling to generate libraries of 
ribosome-protected mRNA fragments that were 
sequenced using Illumina NGS platforms. 
Examination of ribosome footprints led to the 
identification of 751 translated ORFs with only 
147 previously predicted to be coding. These 
included ORFs positioned within existing ORFs 
(both in-frame and out of frame), short ORFs 
upstream of existing ORFs, antisense ORFs and 
short ORFs lying within regions that were 
previously not predicted to be coding. Furthermore, 
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NGS technologies are constantly evolving and 
new developments in single-molecule sequencing 
will open up a completely new set of possibilities 
like the elucidation of DNA modifications [70]. 
These technological developments will have to go 
hand-in-hand with advances in bioinformatics 
algorithms, which is just as major a challenge 
[71]. Finally, an enormous effort lies ahead in 
dissecting the transcriptional regulatory features 
that are being unveiled by genome-wide transcriptome 
analyses. These endeavours will certainly offer 
new insights in HCMV pathogenicity and could 
potentially lead to the development of new 
antiviral therapies. 
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